• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

    12/8/21 5:05:14 PM ET
    $PPD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PPD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    H&F Corporate Investors VIII, Ltd.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PPD, Inc. [ PPD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/08/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/08/2021 S(1) 52,884,036 D $47.5 0 I See Footnotes(2)(11)
    Common Stock 12/08/2021 S(1) 20,244,387 D $47.5 0 I See Footnotes(3)(11)
    Common Stock 12/08/2021 S(1) 3,630,740 D $47.5 0 I See Footnotes(4)(11)
    Common Stock 12/08/2021 S(1) 359,372 D $47.5 0 I See Footnotes(5)(11)
    Common Stock 12/08/2021 S(1) 35,622,429 D $47.5 0 I See Footnotes(6)(11)
    Common Stock 12/08/2021 S(1) 15,987,409 D $47.5 0 I See Footnotes(7)(11)
    Common Stock 12/08/2021 S(1) 3,021,286 D $47.5 0 I See Footnotes(8)(11)
    Common Stock 12/08/2021 S(1) 934,469 D $47.5 0 I See Footnotes(9)(11)
    Common Stock 12/08/2021 S(1) 157,138 D $47.5 0 I See Footnotes(10)(11)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    H&F Corporate Investors VIII, Ltd.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Investors VIII, L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Capital Partners VIII, L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Capital Partners VIII (Parallel), L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    HFCP VIII (Parallel - A), L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H&F Executives VIII, L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H&F Associates VIII, L.P.

    (Last) (First) (Middle)
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    Explanation of Responses:
    1. On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash.
    2. Reflects securities directly held by Hellman & Friedman Capital Partners VII, L.P. ("HFCP VII").
    3. Reflects securities directly held by Hellman & Friedman Capital Partners VII (Parallel), L.P. ("HFCP VII Parallel").
    4. Reflects securities directly held by HFCP VII (Parallel-A), L.P. ("HFCP VII Parallel-A").
    5. Reflects securities directly held by H&F Executives VII, L.P. ("H&F VII Executives", and together with HFCP VII, HFCP VII Parallel and HFCP VII Parallel-A, the "H&F VII Funds").
    6. Reflects securities directly held by Hellman & Friedman Capital Partners VIII, L.P. ("HFCP VIII").
    7. Reflects securities directly held by Hellman & Friedman Capital Partners VIII (Parallel), L.P. ("HFCP VIII Parallel").
    8. Reflects securities directly held by HFCP VIII (Parallel-A), L.P. ("HFCP VIII Parallel-A").
    9. Reflects securities directly held by H&F Executives VIII, L.P. ("H&F VIII Executives").
    10. Reflects securities directly held by H&F Associates VIII, L.P. ("H&F VIII Associates", and together with HFCP VIII, HFCP VIII Parallel, HFCP VIII Parallel-A and H&F VIII Executives, the "H&F VIII Funds").
    11. Hellman & Friedman Investors VII, L.P. ("H&F Investors VII") is the general partner of each of the H&F VII Funds. H&F Corporate Investors VII, Ltd. ("H&F VII") is the general partner of H&F Investors VII. Hellman & Friedman Investors VIII, L.P. ("H&F Investors VIII") is the general partner of each of the H&F VIII Funds. H&F Corporate Investors VIII, Ltd. ("H&F VIII") is the general partner of H&F Investors VIII. A three member board of directors of each of H&F VII and H&F VIII has investment discretion over the shares held by the H&F VII Funds and the H&F VIII Funds, respectively. Allen R. Thorpe, a member of the board of directors of PPD, Inc. is a member of the boards of directors of H&F VII and H&F VIII.
    Remarks:
    Because no more than 10 reporting persons can file any one Form 4 through the Securities and Exchange Commission's EDGAR system, certain affiliates of the Reporting Persons have filed a separate Form 4.
    H&F CORPORATE INVESTORS VIII, LTD. By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    HELLMAN & FRIEDMAN INVESTORS VIII, L.P. By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    HELLMAN & FRIEDMAN CAPITAL PARTNERS VIII, L.P. By: Hellman & Friedman Investors VIII, L.P., as general partner By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    HELLMAN & FRIEDMAN CAPITAL PARTNERS VIII (PARALLEL), L.P. By: Hellman & Friedman Investors VIII, L.P., as general partner By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    HFCP VIII (PARALLEL-A), L.P. By: Hellman & Friedman Investors VIII, L.P., as general partner By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    H&F EXECUTIVES VIII, L.P. By: Hellman & Friedman Investors VIII, L.P., as general partner By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    H&F ASSOCIATES VIII, L.P. By: Hellman & Friedman Investors VIII, L.P., as general partner By: H&F Corporate Investors VIII, Ltd., as general partner By: /s/ Allen R. Thorpe Name: Allen R. Thorpe Title: Vice President 12/08/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPD

    DatePrice TargetRatingAnalyst
    8/5/2021$47.50Neutral
    Credit Suisse
    More analyst ratings

    $PPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/9/21 5:14:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 5:05:14 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:53:26 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    SEC Filings

    See more
    • SEC Form 15-12B filed by PPD, Inc.

      15-12B - PPD, Inc. (0001793294) (Filer)

      12/20/21 5:20:22 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PPD, Inc.

      S-8 POS - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:16:02 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:12:04 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care